AUSTIN, TX / ACCESS Newswire / September 29, 2026 / The first act of the GLP-1 boom was about getting treatment. The second is increasingly about staying on it.

After years defined by shortages, waiting lists and extraordinary demand, obesity medicine is settling into a different kind of reality: refills, follow-up, dose adjustments and the economics of treatment that may extend well beyond the initial weight-loss phase.

T·TIME is launching its injectable program into that second act.

The telehealth company's new cash-pay program for compounded semaglutide and tirzepatide uses a single rate that does not change with the dose prescribed by the treating clinician. Medication, physician review, follow-up visits, 24/7 medical support and next-day cold shipping are included. There is no separate membership fee.

A patient may start at one dose, move upward during titration or later receive a different prescription. The rate does not reset when the prescription changes.

The clinical variable moves. The bill does not.

"Treatment can change over time. We wanted the commercial side to stay still," said Moshe Saraf, founder of T·TIME. "The clinician makes the clinical decision. Changing that decision should not create a second decision about price."

The approach arrives as the GLP-1 category itself is becoming simultaneously larger, more ordinary and more complicated.

Cash-pay and direct-to-patient channels have moved closer to the center of the market, including home-delivery programs run by major manufacturers. At the same time, oral obesity drugs are broadening the category beyond injections, while competition for cash-paying patients has intensified.

What began as a scramble for access is starting to look more like infrastructure.

That shift matters because the spectacular part of weight-loss treatment happens first. The mundane part can last much longer.

Randomized withdrawal trials have repeatedly shown the difficulty of maintaining weight reduction after treatment stops. In the STEP 4 trial, participants who continued semaglutide kept losing weight during the randomized phase, while those switched to placebo regained weight. In SURMOUNT-4, participants switched from tirzepatide to placebo regained an average 14% of body weight during the randomized period, while participants continuing treatment lost additional weight. Those studies involved the drugs and formulations studied in the respective clinical trials; they did not study T·TIME's compounded products.

The result is a new question for the industry. The original GLP-1 question was whether people could get these medicines. The emerging question is what care looks like once they have been using them for months or years.

For cash-paying patients, predictability becomes part of that equation.

T·TIME's answer is deliberately uneventful: one care model, one rate structure, and no new pricing tier when the clinician changes the dose.

The launch also comes during a sharper regulatory turn for compounded GLP-1 products. In 2026, the FDA increased enforcement around misleading promotion of non-FDA-approved compounded semaglutide and tirzepatide, including claims that could imply compounded products are equivalent to FDA-approved medicines. The agency has also taken additional steps concerning the circumstances under which these drugs may be compounded.

T·TIME distinguishes its compounded products from FDA-approved branded medicines throughout the program.

Compounded semaglutide and tirzepatide offered through T·TIME are prescribed only after review by a licensed clinician and are prepared and dispensed by a licensed U.S. compounding pharmacy. They are not Wegovy, Ozempic, Zepbound or Mounjaro, and compounded products are not FDA-approved as finished drugs. Availability and prescribing are subject to applicable federal and state requirements.

Patients who are not medically approved for treatment are refunded.

The program extends the cash-pay structure T·TIME already uses for other prescription treatments, including enclomiphene, sermorelin and its compounded vardenafil-tadalafil treatment, OVERTIME.

For T·TIME, the thesis behind the GLP-1 launch is less about the moment a patient starts than the many ordinary months that may follow.

The first race was for access. The next may be for continuity.

Media Contact
Moshe Saraf
press@ttime.men
T·TIME
ttime.men

SOURCE: T·TIME